Table 1.

The incidence of CIP in real world.

Total number	CIP patients	Incidence rate	Median onset time	Cancer type	ICIs treatment	Refs
101	22	21.78%	4.5 months	lung cancer	anti-PD-1	(1)
315	30	9.50%	1.8 months	lung cancer	anti-PD-1	(3)
270	6	2.22%	not mentioned	lung cancer	anti-PD-1 (89.3%) anti-PD-L1 (10.7%)	(8)
559	23	4.11%	not mentioned	lung cancer	anti-PD-1	(9)
71	22	30.90%	not mentioned	lung cancer	anti-PD-1 (85.9%) anti-PD-L1 (14.1%)	(10)
164	20	12.20%	2.9 months	lung cancer	anti-PD-1,anti-PD-L1	(26)
170	27	15.88%	1.2 months	lung cancer	anti-PD-1	(30)
204	38	18.63%	6.3 months	lung cancer	anti-PD-1 (91.2%) other(10.8%) Combination ICIs(30.9%)	(28)
1826	64	3.50%	2.3 months	lung cancer (75%) melanoma (20.3%) other types (4.7%)	anti-CTLA-4 (6.9%) anti-PD-1 (79.3%) anti-PD-L1 (13.8%)	(29)
406	16	3.94%	Not mentioned	renal cell carcinoma	anti-PD-1	(31)
138	20	14.50%	1.7 months	lung cancer	anti-PD-1	(27)
71	1	1.41%	1.4 months	melanoma	anti-CTLA-4	(32)